[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100156636":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":17,"locations":21,"responsibleParty":34,"collaborators":7,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":7,"eligibilityCriteria":42,"healthyVolunteers":38,"sex":43,"minAge":44,"maxAge":45,"enrollmentInfo":46,"targetDuration":7,"studyType":49,"phases":7,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":54,"whyStopped":7,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":7,"leadSponsor":60,"locationsCount":61},{"fullName":5,"class":6},"King Faisal Specialist Hospital & Research Center","OTHER",null,[9],{"type":10,"name":11,"description":11,"armGroupLabels":7,"otherNames":7},"DRUG","Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab",[13],{"name":14,"affiliation":15,"role":16},"Shouki Bazarbashi, M.D.","KFSH & RC","PRINCIPAL_INVESTIGATOR",[18],{"name":14,"role":19,"phone":20,"phoneExt":7,"email":7},"CONTACT","+966-1-4423949",[22],{"facility":23,"status":24,"city":25,"state":7,"zip":7,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":7},"Kfsh & Rc","RECRUITING","Riyadh","Saudi Arabia","SA",{"type":29,"coordinates":30},"Point",[31,32],46.72185,24.68773,{"lat":32,"lon":31},{"type":35,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100156636","a-trial-of-capecitabine-xeloda-oxaliplatin-and-irinotecan-in-combination-with-bevacizumab-in-1st-line-treatment-of-metastatic-colorectal-cancer-100156636",false,"NCT01311050","A Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer","A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer","Inclusion Criteria:\n\n* Patients with diagnosed Metastatic Colorectal Cancer\n\nExclusion Criteria:\n\n* Patients with diagnosis other than Metastatic Colorectal Cancer","ALL","14 Years","85 Years",{"count":47,"type":48},46,"ESTIMATED","OBSERVATIONAL","A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination with Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer",[52],"Metastatic Colorectal Cancer",[52],"UNKNOWN","2011-12-11",{"date":57,"type":48},"2011-12-13",{"date":59,"type":7},"2009-01",{"name":5,"class":6},1]